Aiko Biotechnology

The University of Arizona

Southern Research Institute

Biousian Biosystems, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

University of New England College of Osteopathic Medicine

Edward J Bilsky

Robin L Polt

Janet Yancey-Wrona

Wolfgang Sadée

Subramaniam Ananthan

Richard B Rothman

Hanoch Senderowitz

Wolfgang Sadee

Frank Porreca

Methods and materials are provided for the production of glycosylated GLP-1 peptides that exhibit improved properties. The methods and materials of the present invention may be used for treatment of metabolic conditions, such as Syndrome X and diabetes.

Glucagon-like peptide-1 glycopeptides

In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject. Such formulations, and methods of using the same, may also deter diversion, inhibit peripheral effects of the opioid agonist, and reduce addiction liability.

Combination analgesic employing opioid agonist and neutral antagonist

A non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects, and insufficient to block substantial central effects, of the opioid agonist in the subject. Such formulations, and methods of using same, may also deter diversion, inhibit peripheral effects, and reduce addiction liability.

Combination analgesic employing opioid and neutral antagonist

Methods and materials are provided for the production of glycosylated peptides that exhibit high affinity and specificity for delta opioid receptors. The methods and materials of the present invention may be used for treatment of conditions involving pain, such as acute pain and nociceptic pain, neuralgia and myalgia.

Delta-opioid receptor selective analgesics

Compounds represented by the formula: wherein R is Calkyl; Ccycloalkylalkyl; or Calkenyl; R' is H or Calkyl; X is H or OH; Y is alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl or aroyl; and Z is CH or N; provided that X is H, when Z is CH and R is Ccycloalkylalkyl or Calkenyl; prodrugs thereof; and pharmaceutically acceptable salts thereof are provided. Compounds of the above formula are useful as analgesics for treating pain; as immunomodulators, to modulate the behavioral effects of drugs of abuse and to modulate the development of tolerance and dependence to &#x3bc; agonists.

Pyridomorphinans, pyridazinomorphinans and use thereof

Amphipathic glycopeptides, the amino acid sequence of which comprises an N-terminal opioid message sequence, a C-terminal helical address sequence, and a linker sequence between the message sequence and the helical address sequence, where the C-terminal helical address sequence has a length of nine amino acids, and at least one of the amino acid residues of the peptide is glycosylated. The peptides are useful for relieving pain, providing analgesia and treating anxiety, depression, obesity, anorexia nervosa, phobias, schizophrenia, Parkinson's disease and Alzheimer's disease.

Growing community of inventors

Biddeford, ME, United States of America

Edward J Bilsky